Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
CymaBay Therapeutics, Inc. (CBAY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/18/2023 |
4
| McWherter Charles (President of R&D) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold 21,746 shares
@ $11.4669, valued at
$249.4k
Exercised 10,404 options to buy
@ $5, valued at
$52k
Exercised 708 options to buy
@ $5, valued at
$3.5k
Exercised 236 options to buy
@ $5, valued at
$1.2k
Exercised 3,892 options to buy
@ $5, valued at
$19.5k
Exercised 6,506 options to buy
@ $5, valued at
$32.5k
|
|
| 08/16/2023 |
4
| Menold Daniel (Vice President, Finance) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold shares
@ $11.9158, valued at
$0
Sold shares
@ $12.1293, valued at
$0
Exercised 8,500 options to buy
@ $1.06, valued at
$9k
Exercised 7,000 options to buy
@ $10, valued at
$70k
|
|
| 08/16/2023 |
4
| Quinlan Paul T (General Counsel) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $11.9101, valued at
$59.6k
Exercised 5,000 options to buy
@ $2.94, valued at
$14.7k
|
|
| 08/11/2023 |
4
| Menold Daniel (Vice President, Finance) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold 20,945 shares
@ $12.3535, valued at
$258.7k
Exercised 14,459 options to buy
@ $5, valued at
$72.3k
Exercised 6,486 rights
@ $5, valued at
$32.4k
|
|
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/30/2023 |
4
| Quinlan Paul T (General Counsel) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $10.05, valued at
$50.3k
Exercised 5,000 options to buy
@ $2.94, valued at
$14.7k
|
|
| 05/19/2023 |
4
| McWherter Charles (President of R&D) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold 21,749 shares
@ $9.0757, valued at
$197.4k
Exercised 10,407 options to buy
@ $5, valued at
$52k
Exercised 708 options to buy
@ $5, valued at
$3.5k
Exercised 236 options to buy
@ $5, valued at
$1.2k
Exercised 3,892 options to buy
@ $5, valued at
$19.5k
Exercised 6,506 options to buy
@ $5, valued at
$32.5k
|
|
| 05/17/2023 |
4
| Quinlan Paul T (General Counsel) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $10.3662, valued at
$51.8k
Exercised 5,000 options to buy
@ $2.94, valued at
$14.7k
|
|
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/30/2023 |
4
| Avoro Capital Advisors LLC (10% Owner) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Bought 2,142,857 options to buy
@ $0.0001, valued at
$214.3 |
|
| 01/27/2023 |
4
| Dorling Janet (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.8, valued at
$195k
|
|
| 01/27/2023 |
4
| EMSTER KURT VON (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.8, valued at
$195k
|
|
| 01/27/2023 |
4
| WIGGANS THOMAS G (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.8, valued at
$195k
|
|
| 01/27/2023 |
4
| Loewy Caroline M (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.8, valued at
$195k
|
|
| 01/27/2023 |
4
| Wills Robert James (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.8, valued at
$195k
|
|
| 01/27/2023 |
4
| Lefebvre Eric (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $7.8, valued at
$195k
|
|
| 01/27/2023 |
4
| KIM DENNIS D (Chief Medical Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 180,000 options to buy
@ $7.8, valued at
$1.4M
|
|
| 01/27/2023 |
4
| Shah Sujal (CEO) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 800,000 options to buy
@ $7.8, valued at
$6.2M
|
|
| 01/27/2023 |
4
| McWherter Charles (President of R&D) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $7.8, valued at
$2.3M
|
|
| 01/27/2023 |
4
| Dickinson Klara (Chief Regulatory Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 215,000 options to buy
@ $7.8, valued at
$1.7M
|
|
| 01/27/2023 |
4
| STUART LEWIS J (Chief Commercial Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 215,000 options to buy
@ $7.8, valued at
$1.7M
|
|
| 01/27/2023 |
4
| Menold Daniel (Vice President, Finance) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $7.8, valued at
$780k
|
|
| 01/27/2023 |
4
| Quinlan Paul T (General Counsel) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 215,000 options to buy
@ $7.8, valued at
$1.7M
|
|
| 06/07/2022 |
4
| Shah Sujal (CEO) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Bought 51,301 shares
@ $1.95, valued at
$100k
|
|
| 03/21/2022 |
4
| Lefebvre Eric (Director) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $3.21, valued at
$369.2k
|
|
| 01/27/2022 |
4
| Quinlan Paul T (General Counsel) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $2.94, valued at
$588k
|
|
| 01/27/2022 |
4
| Menold Daniel (Vice President, Finance) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 75,000 options to buy
@ $2.94, valued at
$220.5k
|
|
| 01/27/2022 |
4
| Dickinson Klara (Chief Regulatory Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 175,000 options to buy
@ $2.94, valued at
$514.5k
|
|
| 01/27/2022 |
4
| STUART LEWIS J (Chief Commercial Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 116,667 options to buy
@ $2.94, valued at
$343k
|
|
| 01/27/2022 |
4
| KIM DENNIS D (Chief Medical Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 133,333 options to buy
@ $2.94, valued at
$392k
|
|
| 01/27/2022 |
4
| McWherter Charles (Chief Scientific Officer) has filed a Form 4 on CymaBay Therapeutics, Inc.|
Txns:
| Granted 225,000 options to buy
@ $2.94, valued at
$661.5k
|
|
|
|
|